Acquisition Closed September 8, 2026
Forte Biosciences, Inc. acquisition by argenx BV (closed): stock options and RSUs
Completed: SEC filings show this deal closed by September 8, 2026. argenx bought Forte Biosciences through a $77.00-per-share cash tender offer.
- Buyer
- argenx BV
- What holders receive
- $77.00 per share in cash
- Agreement signed
- July 26, 2026
- Shareholder vote
- —
- Expected closing
- Not stated in the filing
- Closed
- September 8, 2026
How equity awards are treated
The filing's equity award section could not be summarized reliably. Read the source filing below.
Estimate your payout at $77.00 per share
Options pay the spread between the deal price and the exercise price; options priced at or above $77.00 usually pay nothing. Whether unvested awards pay now or later depends on the treatment above. Before taxes.
What this means for your taxes
- Shares you own outright are sold for cash at closing. That is a taxable sale: the gain over your cost basis is a capital gain, long-term if you have held the shares more than a year at closing. For shares from vested RSUs, your basis is generally the value already taxed at vesting (it was on your W-2).
- ESPP shares sold in the deal within 2 years of the offering date or 1 year of purchase are a disqualifying disposition: part of the gain is taxed as ordinary income.
General rules, not advice for your situation. Your award agreement and the merger agreement control. Full guide: stock options and RSUs in an acquisition →
Source
From the company's SEC filing: SC 14D9 (accession 0001140361-26-031507). Last checked against the filing on November 19, 2026. Found an error? Corrections are made the same day; see how we check.
Questions
What will Forte Biosciences, Inc. shareholders receive?
Under the merger agreement, holders receive $77.00 per share in cash.
What happens to Forte Biosciences, Inc. stock options and RSUs?
See the treatment of equity awards section in the source filing.
When will the deal close?
The filing does not give a specific closing date; closing depends on approvals. SEC filings show it closed by September 8, 2026.